Victory Capital Management Inc. Makes New Investment in Indivior PLC $INDV

Victory Capital Management Inc. bought a new position in Indivior PLC (NASDAQ:INDV) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 806,191 shares of the company’s stock, valued at approximately $19,437,000.

Several other institutional investors and hedge funds have also recently modified their holdings of INDV. Goldman Sachs Group Inc. boosted its stake in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares in the last quarter. Jane Street Group LLC raised its holdings in Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after buying an additional 958,132 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Indivior in the second quarter worth about $768,000. Rathbones Group PLC lifted its stake in shares of Indivior by 294.9% in the second quarter. Rathbones Group PLC now owns 56,015 shares of the company’s stock worth $832,000 after buying an additional 41,831 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Indivior by 124.4% during the second quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company’s stock valued at $21,977,000 after buying an additional 827,230 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Keith Humphreys bought 775 shares of the stock in a transaction dated Monday, January 5th. The shares were purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director owned 5,802 shares of the company’s stock, valued at $205,332.78. This represents a 15.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Stejbach bought 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were bought at an average price of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. The trade was a 4.82% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 4,871 shares of company stock valued at $172,385.

Indivior Stock Up 2.3%

Shares of Indivior stock opened at $33.34 on Wednesday. The company has a market capitalization of $4.17 billion, a price-to-earnings ratio of 20.33 and a beta of 0.83. The stock’s 50-day simple moving average is $33.99 and its 200-day simple moving average is $30.51. Indivior PLC has a 52 week low of $8.64 and a 52 week high of $38.00.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. On average, equities analysts expect that Indivior PLC will post 1.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a research report on Wednesday, December 3rd. HC Wainwright boosted their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Northland Securities set a $50.00 price target on Indivior in a report on Tuesday, January 20th. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Finally, Weiss Ratings raised Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday, March 2nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.